Background. The mammalian target of rapamycin (mTOR) is known to stimulate a variety of transport mechanisms including the intestinal phosphate transporter NaPi-IIb. The present study was performed to elucidate whether mTOR similarly regulates the major renal tubular phosphate transporter NaPi-IIa. Methods. To this end, NaPi-IIa was expressed in Xenopus oocytes with or without mTOR and phosphate transport estimated from phosphate-induced (1 mM) current (I pi ). Results. As a result, I pi was observed in NaPi-IIa-expressing but not in H 2 O-injected Xenopus oocytes. Co-expression of mTOR significantly enhanced I pi in NaPi-IIa-expressing Xenopus oocytes, an effect abrogated by treatment with rapamycin (50 nM for the last 24 h of incubation). In a second series of experiments, the effect of rapamycin was analysed in mice. The in vivo administration of rapamycin (3 µg/g body weight/day) for 3 days resulted in phosphaturia in mice despite a tendency of plasma phosphate concentration to decrease. Conclusions. mTOR contributes to the regulation of renal phosphate transport, and rapamycin thus influences phosphate balance.
Introduction
Rapamycin is the classical inhibitor of the serine/threonine kinase mammalian target of rapamycin (mTOR) [1] . Pharmacological inhibition of the kinase by rapamycin or further drugs is applicable in a wide variety of disorders including autoimmune diseases [2] [3] [4] , cancer [5] [6] [7] [8] [9] , ventricular hypertrophy [10] and polycystic kidney disease [11] [12] [13] . Most recently, rapamycin was shown to extend the life span of mice [14] . mTOR is a nutrient sensor [15, 16] and is further stimulated by growth factors [17] , insulin [18] and leptin [19] . mTOR plays a pivotal role in the regulation of cell proliferation and cell growth [17] as well as of cell death [20] . The kinase is inhibited during hypoxia [21] . mTOR enhances cellular amino acid uptake [22] and protein synthesis [21] . The kinase stimulates the serum-and glucocorticoid-inducible kinase SGK1 [23] , a regulator of a wide variety of transport systems [24] . Carriers regulated by mTOR and SGK1 include the intestinal phosphate transporter SLC34A2 [25] . Thus, the possibility must be considered that mTOR is similarly involved in the regulation of renal tubular phosphate transport. As a matter of fact, clinical evidence suggests an effect of rapamycin on phosphate balance [26] .
A negative phosphate balance may interfere with adequate bone mineralization [27] . On the other hand, excess phosphate may foster calcium phosphate precipitations outside of bone leading to the development of cardiovascular disease [28] [29] [30] and accelerated ageing [31, 32] . The phosphate balance is determined by phosphate transport in the intestine and kidney, which are under tight hormonal regulation [33] [34] [35] .
Renal tubular phosphate transport is in large part accomplished by cellular uptake of phosphate across the apical membrane of proximal tubular cells [36] by the Na + -coupled phosphate transporter NaPi-IIa [34, 36] , which operates in parallel to NaPi-IIc and Pit-2 [37] [38] [39] . NaPiIIa is downregulated by parathyroid hormone (PTH), which is at least partially effective through cAMP [34] . In addition, renal tubular phosphate transport, and thus renal phosphate excretion are regulated by insulin [40, 41] and insulin-like growth factor IGF1 [42] , known stimulators of mTOR and SGK1 [43] . However, little is known about the signalling mediating the effect of insulin or IGF1 on renal tubular phosphate transport.
The present study explored the possibility that rapamycin influences the activity of the renal tubular transporter NaPi-IIa. To this end, in vitro regulation of NaPi-IIa by mTOR was studied in the Xenopus oocyte expression system, and the effect of rapamycin on urinary excretion of phosphate was determined.
Materials and methods

In vitro expression
For generation of cRNA, constructs were used encoding wild-type murine NaPi-IIa [44] and rat mTOR [25] . The cRNA was generated as described previously [45, 46] . The cDNA encoding NaPi-IIa was kindly provided by Heini Murer. For electrophysiology, Xenopus oocytes were prepared as previously described [46, 47] . Fifteen nanogram of wild-type mTOR was injected on the first day and 15 ng NaPi-IIa cRNA on the second day after preparation of the Xenopus oocytes. All experiments were performed at room temperature 4-5 days after the second injection. Two-electrode voltage-clamp recordings [48] were performed at a holding potential of −50 mV. The data were filtered at 10 Hz and recorded with a GeneClamp 500 amplifier, a DigiData 1300 A/D-D/ A converter and the pClamp 9.0 software package for data acquisition and analysis (Axon Instruments, USA). The control solution (superfusate/ ND96) contained 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 and 5 mM HEPES, pH 7.4. Phosphate was added to the solutions at the indicated concentrations. The final solutions were titrated to pH 7.4 using NaOH. The flow rate of the superfusion was 20 ml/min, and a complete exchange of the bath solution was reached within about 10 s. Where indicated, n represents the number of oocytes investigated. All experiments were repeated with at least two batches of oocytes; in all repetitions, qualitatively similar data were obtained.
In vivo function
All animal experiments were conducted according to the German law for the welfare of animals and were approved by local authorities.
For evaluation of renal excretion, SV129 mice (males, 12 weeks old, n = 31) were placed individually in metabolic cages (Techniplast, Hohenpeissenberg, Germany) for 24-h urine collection as described previously [49] . They were allowed a 3-day habituation period during which food and water intake, urinary flow rate, urinary excretion of salt and body weight were recorded daily to ascertain that the mice were adapted to the new environment. Subsequently, 24-h collection of urine was performed for three consecutive days in order to obtain the urinary parameters. Rapamycin (Merck, Biosciences, Schwalbach, Germany) was administered [3 µg/g body weight (BW)/day] i.p. for 3 days. To assure quantitative urine collection, metabolic cages were siliconized, and urine was collected under water-saturated oil.
To obtain blood specimens, animals were lightly anaesthetized with diethylether (Roth, Karlsruhe, Germany), and ∼150 μl of blood was withdrawn into heparinized capillaries by puncturing the retro-orbital plexus.
Urinary phosphate concentration was determined colorimetrically utilizing a commercial diagnostic kit (Roche, Mannheim, Germany). Urinary concentration of Ca 2+ was measured by flame photometry (ELEX 6361, Eppendorf, Germany). Plasma Ca 2+ and phosphate concentrations were determined using a photometric method (FUJI FDC 3500i, Sysmex, Norsted, Germany). Plasma glucose concentrations were determined utilizing a glucometer (Accutrend, Roche, Mannheim, Germany). Urinary glucose concentrations were measured utilizing a commercial enzymatic kit (gluco-quant, Roche, Mannheim, Germany). Creatinine concentrations in urine were determined using the Jaffe reaction (Sigma, Schnelldorf, Germany), and creatinine concentrations in serum were measured using a photometric method according to the manufacturer's instructions (dri-chem clinical chemistry analyser FUJI FDC 3500i). Amino acid concentrations in urine and serum were measured by HPLC as described before [50] . Plasma parathormone concentration was measured using an ELISA kit (Immunotopics, San Clemente, USA). A radioimmunoassay kit was employed to determine the concentration of 1,25(OH)-vitamin D 3 (IDS, Boldon, UK) in plasma. FGF23 plasma concentration was measured using an ELISA kit (FGF23 mouse ELISA kit, Immutopics).
Immunohistochemistry
Kidneys were fixed with 4% paraformaldehyde, thereafter incubated in 30% sucrose overnight and frozen in Tissue Tek (Polyscience, Niles, IL). Then, 12-µm cryosections were prepared. For immunohistochemistry, cryosections were air-dried, treated with a fixation solution (4% PFA/ PBS, 0.2% Igepal, 0.1% Na-desoxycholate) for 5 min and then washed with PBS. Thereafter, the slides were incubated for 30 min at room temperature in blocking solution (3% NGS, 2% BSA, 0.5% Igepal) then incubated overnight at 4°C with the primary antibodies diluted in carrier solution (2% BSA, 0.5% Igepal). On the next day, the slides were washed with PBS followed by another incubation step with blocking solution for 15 min at room temperature. Then, the secondary antibody diluted in carrier solution was added, and the slides were incubated for 1 h at room temperature followed by washing with PBS. Finally, the sections were covered with mounting medium (ProLong ® Gold Antifade Reagent, Invitrogen, Karlsruhe, Germany) and stored at 4°C in the dark until analysis. A primary antibody directed against NaPi2A from LIFESPAN Biosciences (1:100) was used. Secondary antibody (1:2000) was Alexa Fluor Fig. 1 . Co-expression of mTOR stimulates electrogenic phosphate transport in NaPi-IIa-expressing Xenopus oocytes. A. Original tracings showing phosphate-induced (1 mM) currents (I Pi ) in Xenopus oocytes injected with water without (a) or with NaPi-IIa cRNA without (b) or with (c) additional co-expression of mTOR. B. Arithmetic means ± SEM (n = 32-74) of phosphate-induced (1 mM) currents (I Pi ) in Xenopus oocytes injected with water (left bar) without or with NaPi-IIa without (middle bar) or with (right) additional co-expression of mTOR. ***P < 0.001 indicates statistically significant difference from absence of NaPi-IIa. ###P < 0.001 indicates statistically significant difference from absence of mTOR. C. Arithmetic means ± SEM (n = 10-13) of inward current as a function of phosphate concentration in Xenopus oocytes expressing NaPi-IIa without and with mTOR. The difference from the absence of mTOR is statistically significant (P < 0.05) at each concentration of phosphate >3 µM.
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488 goat α-rabbit, and Draq5 (1:1000; Biostatus Limited, Shepshed, UK) was used for nuclear staining.
Calculations
Data are provided as means ± SEM, and n represents the number of independent experiments. Data were tested for significance using paired or unpaired Student's t-test or ANOVA. Only results with P < 0.05 were considered statistically significant.
Results
Dual-electrode voltage-clamp experiments in Xenopus oocytes were performed to elucidate, whether the major renal tubular phosphate transporter, NaPi-IIa, is regulated by mTOR. In Xenopus oocytes injected with water alone, phosphate (1 mM) did not induce a significant current indicating that Xenopus oocytes do not express appreciable electrogenic phosphate transport ( Figure 1A and B). In oocytes injected with cRNA encoding NaPiIIa, however, the addition of phosphate (1 mM) to the extracellular bath solution induced an inward current (Ip i ). The co-expression of mTOR significantly increased Ip i in NaPi-IIa-expressing Xenopus oocytes ( Figure 1A and B). Expression of mTOR alone yielded a phosphate-induced current of 3.3 ± 0.3 nA (n = 10), a current not significantly different from the phosphate-induced current in oocytes injected with water alone (2.8 ± 0.4 nA; n = 8). Accordingly, mTOR stimulates electrogenic phosphate transport through NaPi-IIa. Exposure of NaPi-IIa-expressing Xenopus oocytes to phosphate concentrations ranging from 0 to 3 mM ( Figure 1C ) yielded concentration-dependent currents which resulted in a maximal current of 71 ± 2 nA. The phosphate concentration needed for half-maximal current (K M ) was 50 ± 7 µM. The co-expression of mTOR did not significantly modify K M (61 ± 5 µM), but significantly increased the maximal current (to 125 ± 2 nA). Additional experiments were performed to test whether NaPi-IIa is inhibited by rapamycin. Irrespective of the presence or absence of rapamycin, the injection of water did again not result in a significant Ip i (Figure 2) . The expression of NaPi-IIa was followed by the appearance of Ip i , which was again enhanced by the additional expression of mTOR. Rapamycin (50 nM) did not significantly modify Ip i in Xenopus oocytes expressing NaPi-IIa alone, but significantly decreased Ip i in Xenopus oocytes expressing both NaPi-IIa and mTOR when present for the last 24 h of incubation. In the presence of rapamycin, Ip i was not significantly different in Xenopus oocytes expressing NaPi-IIa and mTOR and Xenopus oocytes expressing NaPi-IIa alone (Figure 2) . In a separate series of experiments, the normalized phosphate-induced current was 1.00 ± 0.02 (n = 9) in oocytes expressing both NaPi-IIa and mTOR in the absence and 0.58 ± 0.04 (n = 9 P < 0.01 vs. absence of rapamycin) in the presence of 50 nM rapamycin for the last 24 h of incubation and 0.66 ± 0.06 (n = 9; P < 0.01 vs. absence of rapamycin), if rapamycin had been present for 12 h and then discontinued for further 12 h within the last 24 h of incubation. Accordingly, NaPi-IIa could be inhibited in the oocyte system by rapamycin, an effect apparently not rapidly reversible. To explore whether the in vitro regulation of NaPi-IIa by mTOR and its inhibition by rapamycin are relevant for renal elimination of phosphate in vivo, metabolic cage experiments were performed in mice without and with rapamycin treatment (3 µg/g BW/day i.p.).
BW was similar prior to and following rapamycin treatment (Table 1) . Similarly, creatinine clearance and urinary flow rate as well as plasma concentrations of phosphate and glucose were not significantly modified by rapamycin treatment (Table 1) . Rapamycin treatment was, however, followed by a marked and statistically significant increase in urinary phosphate excretion (Figure 3) . Blotting urinary phosphate excretion versus plasma phosphate concentration revealed that the phosphaturia was not secondary to hyperphosphataemia.
Urinary Ca 2+ excretion tended to be slightly lower in the rapamycin-treated group (0.63 ± 0.08 µg/24 h/g BW, n = 12) than in the control group (0.73 ± 0.17 µg/24 h/g BW, n = 12), a difference, however, not reaching statistical significance.
Glucose excretion was significantly larger following rapamycin treatment (5.96 ± 0.53 ng/24 h/g BW, n = 12) than in the control group (4.20 ± 0.54 ng/24 h/g BW, n = 12). Rapamycin treatment further significantly increased the sum of amino acid excretion (from 36.2 ± 10.7 mmol/mol creatinine, n = 3, to 63.3 ± 17.8 mmol/ mol creatinine, n = 3, P < 0.001). Table 2 lists the excretion of the various individual amino acids. Rapamycin further significantly increased the excretion of ureidopropionic acid (Table 2) . Accordingly, the effect of rapamycin apparently affects several proximal tubular transport processes.
In theory, the rapamycin-induced phosphaturia could have been secondary to altered hormone release. Thus, plasma concentrations of PTH and 1,25(OH) 2 D 3 were determined. As listed in Table 1 , rapamycin did not alter PTH plasma concentration and tended to increase the plasma concentration of 1,25(OH) 2 D 3 . Treatment of rapamycin significantly decreased FGF23 plasma concentrations from 511 ± 62 pg/ml (n = 13) to 367 ± 41 pg/ml (n = 18).
Immunohistochemistry did not reveal an appreciable influence of rapamycin on the NaPi-IIa protein abundance in the brush border membrane (Figure 4) .
Discussion
The present study reveals a novel regulator of renal tubular phosphate transport, i.e. mTOR. As disclosed by the Xenopus oocyte experiments, mTOR is a potent stimulator of NaPi-IIa activity, an effect abrogated by rapamycin. The in vivo significance of mTOR-sensitive regulation of NaPiIIa is illustrated by the phosphaturia following treatment of mice with rapamycin. Proximal tubular phosphate reabsorption involves not only NaPi-IIa, but as well NaPiIIc and Pit-2, both additional phosphate carriers in the apical brush border membrane [37] [38] [39] . Thus, the phosphaturia following rapamycin could be in part due to downregulation of those carriers. The mechanisms underlying the upregulation of NaPiIIa by mTOR are not entirely clear. As maximal transport rate is increased, mTOR could be effective by enhancing the carrier protein abundance within the cell membrane. The immunohistochemistry does not support this possibility, even though it cannot rule out minor alterations of protein abundance. It should be kept in mind that rapamycin may influence transport indirectly, e.g. by modifying the chemical Na + gradient. Apparently, rapamycin induces loss of glucose, phosphate and most amino acids into urine. This is compatible with the presence of a mild Fanconi syndrome and suggests that mTOR either is involved in the regulation of many more proximal tubular transporters or causes a mild, but more generalized damage of the proximal tubule [51] [52] [53] .
In any case, the phosphaturia following rapamycin treatment cannot be explained by increased plasma phosphate concentration. Moreover, the phosphaturia is not explained by increased plasma levels of PTH, the major regulator of renal phosphate transport [34] . PTH fosters the internalization and subsequent degradation of NaPi-IIa, [34] hanced by the decreased phosphate entry across the apical membrane during rapamycin treatment. The renal 1α-hydroxylase is further stimulated by PTH [56] . Moreover, FGF23 is a potent inhibitor of the renal 1α-hydroxylase, and the decrease in FGF23 plasma concentration could contribute to or even account for the increase in calcitriol concentration [57, 58] . The decline of FGF23 would, however, be rather expected to increase renal tubular phosphate reabsorption [57, 58] . As 1,25(OH) 2 D 3 is a powerful stimulator of intestinal phosphate transport [59] , enhanced plasma 1,25(OH) 2 D 3 concentration could increase intestinal phosphate uptake and thus prevent hypophosphataemia despite renal phosphate loss during rapamycin treatment.
At least in theory, renal phosphate loss may compromise bone mineralization. Phosphate is known to inhibit the generation of new osteoclasts and to foster apoptosis of mature osteoclasts [60] . Accordingly, renal phosphate loss may lead to loss of bone minerals. During rapamycin treatment, however, the phosphaturia is not paralleled by hypophosphataemia and is presumably compensated by enhanced formation of 1,25(OH) 2 D 3 , which is expected to stimulate intestinal phosphate absorption and to counteract demineralization of bone.
In conclusion, mTOR is a potent stimulator, and rapamycin is an inhibitor of renal tubular phosphate transport. Rapamycin enhances renal phosphate excretion and in turn increases the formation of 1,25(OH) 2 D 3 . The present observations thus disclose a novel mechanism contributing to the regulation of phosphate metabolism.
